Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Saved in:
| Title: | Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. |
|---|---|
| Authors: | Rodler E; Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Sharma P; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA. Electronic address: psharma2@kumc.edu., Barlow WE; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gralow JR; Department of Breast Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA., Puhalla SL; Division of Hematology/Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA., Anders CK; Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Goldstein L; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brown-Glaberman UA; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA; New Mexico MU-NCORP, Albuquerque, NM, USA., Huynh TT; Department of Hematology/Oncology, Kaiser Permanente NCORP, Anaheim, CA, USA; Kaiser Permanente Medical Group, Anaheim, CA, USA., Szyarto CS; Department of Hematology/Oncology, Genesee Hematology Oncology PC, Flint, MI, USA; Michigan CRC NCORP, Flint, MI, USA., Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Pathak HB; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Swisher EM; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA., Radke MR; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA., Timms KM; Department of Research, Myriad Genetics, Salt Lake City, UT, USA., Lew DL; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Miao J; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Pusztai L; Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Hayes DF; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2023 Feb; Vol. 24 (2), pp. 162-174. Date of Electronic Publication: 2023 Jan 06. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
